Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHORD1 - CHOlesterol Lowering and Residual Risk in Diabetes, Type 1
NCT05641753Phase 4Recruiting
- Sponsor
- NYU Langone Health
- Start
- Dec 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab, atorvastatin, ezetimibe in type 1 diabetes mellitus (T1D), hypercholesterolemia, sponsored by NYU Langone Health. Started Dec 2022; status: recruiting.
02
Drugs
evolocumabatorvastatinezetimibe
03
Conditions
type 1 diabetes mellitus (T1D)hypercholesterolemia
Beyond the preview
Go deeper on NCT05641753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641753.